<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: <z:hpo ids='HP_0002140'>Ischemic stroke</z:hpo> is a major cause of <z:hpo ids='HP_0011420'>death</z:hpo> worldwide but lacks viable treatment or treatment targets </plain></SENT>
<SENT sid="1" pm="."><plain>Monocyte locomotion inhibitory factor (MLIF) is a small heat-stable <z:chebi fb="0" ids="48545">pentapeptide</z:chebi> produced by Entamoeba histolytica in axenic culture, which is supposed to protect the brain from ischemic injury; the mechanism, however, remains unknown </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we further investigated the mechanism underlying the protective role of MLIF in <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: A middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> model in rats was used for detecting the effect of MLIF in the <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> in vivo </plain></SENT>
<SENT sid="4" pm="."><plain>To identify targets of MLIF in brain endothelial cells, we performed immunoprecipitation of <z:chebi fb="1" ids="15956">biotin</z:chebi>-conjugated MLIF and mass spectrometry </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: MLIF can protect the brain from ischemic injury in vivo, yielding decreased ischemic volume, prolonged survival, and improved neurological outcome </plain></SENT>
<SENT sid="6" pm="."><plain>In vitro studies showed that MLIF displayed protective effects through inhibition of expression of pathological inflammatory <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecules and enhancing endothelial nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase expression and nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> release in the cerebrovascular endothelium </plain></SENT>
<SENT sid="7" pm="."><plain>The target screening experiments demonstrated binding of MLIF to the ribosomal protein translation elongation factor eEF1A1 </plain></SENT>
<SENT sid="8" pm="."><plain>MLIF enhanced endothelial nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase expression through stabilization of endothelial nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase <z:chebi fb="2" ids="33699">mRNA</z:chebi>, and eEF1A1 was shown to be necessary for this enhanced expression </plain></SENT>
<SENT sid="9" pm="."><plain>Knockdown of eEF1A1 or inhibition of endothelial nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase attenuated MLIF-mediated inhibition of <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule expression </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: In this study, we identified a new potential pharmacologically targetable mechanism underlying MLIF's protective effects in <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> through the eEF1A1/endothelial nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase pathway </plain></SENT>
</text></document>